Mesoblast Limited (NASDAQ: MESO) shares are 139.62% up in the year-to-date (YTD) period and have moved -5.56% or -$1.04 lower in the latest trading session. However, stock’s trailing 12-month performance remains nearly +466.01% lower. Comparatively, the stock is -17.01% down YTD and 35.95% over the trailing 3-month period. If we look at the shorter duration, its week performance is -6.66% and 41.39% over the month.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
On May 28, 2020, H.C. Wainwright recommended the MESO stock is a Buy, while earlier, Maxim Group had Reiterated the stock as a Buy on August 14, 2020. 7 analysts offering the recommendations for the stock have a consensus rating of 1.80 to suggest that the MESO stock is a “Strong Buy. 0 of the 7 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 6 recommend buying, with 0 rating it as an Overweight.
The stock currently trades at $17.66 and analysts tracking its performance over the next 12 months have a consensus estimate price target of $19.25. The forecasts give the Mesoblast Limited stock a price target range of $26.41 on the higher side while at least one analyst think the stock could plunge to a low of $7.53. The two limits represent an upside potential of 33.13% or -134.53%.
Analysts estimate the earnings to increase 17.60% in the current quarter to -$0.16, up from the -$0.21 reported in the same quarter a year ago. For the current year, earnings should grow to an average of -$0.64, up 179.90% from -$0.91 reported last year. Analysts also offered guidance for the next financial quarter, with their average projected EPS at between -$0.2 and -$0.01. Wall Street estimates earnings per share to be at an average of -$0.3 for the next year.
Heat Biologics Inc. (NASDAQ:HTBX), on the other hand, is trading around $1.33 with a market cap of $199.02M and analyst research firms have a positive stance on its shares. Some analysts are even forecasting $Financial Services per share in earnings this year on a short term (1 year) basis.
Let us briefly look at the Heat Biologics Inc. (HTBX) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.
Company balance sheet and cash flow
HTBX’s operating expenses over the recent quarter were at -$4.84 million. This represented a 916.53% of the company’s total revenues which amounted $0.59 million. With this in place, we can see that the company’s diluted EPS declined -$0.05 on the year-over-year period, shrinking to -$0.14 as given in the last earnings report.
In terms of the balance sheet & cash flow as of Name, the total assets figure advanced to $58.15 million from $37.82 million over the previous quarter. Short term investments amounted to $26.31 million while total current assets were at $47.6 million. The cash flow from operating activities totaled -$10.07 million, significantly lower than the -$8.24 million reported in the year-ago quarter. The company’s free cash flow for the quarter was -$10.29 million.
Insiders have transacted a total of 2 times at Heat Biologics Inc. over the last 6 months, with insider purchases undertaken 1 times and accounting for 15,625 shares. Insider sales totaled 4,440 shares over the same period, with these deals completed in 1 transactions. Looking at these numbers, we realize that net purchases over that period are 0.0 shares. Insiders now hold a total of ProShares Short 7 10 Year Treas shares after the latest sales, with American Funds High-Income Trus net shares purchased.
Insiders own 6.04% of the company shares, while shares held by institutions stand at 13.00% with a share float percentage of 75.53M.